pharmaphorum
MARCH 12, 2021
EU regulators are reviewing reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from Pfizer/BioNTech, AstraZeneca and Moderna. The experts have also recommended a safety update on the label of Oxford University/AstraZeneca’s COVID-19 vaccine, which has been linked to anaphylactic reactions, in what has turned out to be a concerning week for vaccine safety.
Outsourcing Pharma
MARCH 8, 2021
Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
MARCH 8, 2021
The PharmaTimes International Clinical Researcher of the Year is calling on the most talented clinical researchers to try their hand and reap the rewards in the 2021 competition.
Pharma Mirror
MARCH 8, 2021
Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very normal (thirty percent of total cases of NSCLS) in people. [1] It became continually challenging in targeting KRAS transformation bearing tumors in view of the unclear con
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 10, 2021
There is no clear evidence that the UK’s £37 billion NHS Test and Trace programme (NHST&T) has an impact on the pandemic, according to a withering report from an influential committee of MPs. In its report the Public Accounts Committee (PAC) noted that Department of Health and Social Care justified the scale of the investment in part on the basis that an effective test and trace system would help avoid a second national lockdown.
Drug Patent Watch
MARCH 8, 2021
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of excipients (inactive ingredients) in drugs, and integrated it with our…. The post Connecting Excipients with Drug Patents – New DrugPatentWatch module appeared first on DrugPatentWatch - Make Better Decisions.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
MARCH 9, 2021
The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.
pharmaphorum
MARCH 11, 2021
European safety regulators have launched an investigation into the safety of a batch of the Oxford University/AstraZeneca COVID-19 vaccine, as countries including Denmark suspended its use as a precaution following reports of blood clots. Initial findings showed no issue with the shots suspended by Austrian authorities after a person was diagnosed with severe blood clotting and died 10 days after vaccination.
Drug Patent Watch
MARCH 10, 2021
Annual Drug Patent Expirations for AXUMIN Axumin is a drug marketed by Blue Earth and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Blue Earth drug AXUMIN appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
MARCH 8, 2021
Data from two Phase III studies demonstrated durable viral suppression in HIV-1 patients
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
MARCH 8, 2021
The DT Clinical Trial Digital Tracker Survey indicates many trial professionals often are hesitant to dive fully into digital technology integration.
pharmaphorum
MARCH 9, 2021
Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. COVID has seen pharma sales experience three years’ worth of digital transformation in the space of just a few months – but while the industry has embraced digital tools and techniques, most companies are still far from
NY Times
MARCH 11, 2021
Millions of people have received the vaccine without safety problems, and there is no evidence of any causal link between the vaccine and blood clots.
Pharma Times
MARCH 11, 2021
Senior leaders from UK and European pharma have come together to judge the Patient Partnership Index 2021
Pharma Mirror
MARCH 12, 2021
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVI
pharmaphorum
MARCH 9, 2021
A smartphone app that uses artificial intelligence to assess the sound of coughing has been launched in the UK, and according to its developer could be an early warning system for COVID-19 and other diseases of the lung. . Hyfe uses acoustic technology to track users’ coughing habits, gauging factors like volume, frequency, amplitude and context, whilst running in the background on an iOS or Android device.
NY Times
MARCH 9, 2021
The steep decline in oversight has stalled a number of new drug applications. The agency says it is trying to protect its employees but critics say inspectors should be considered essential workers and do their jobs.
Pharma Times
MARCH 10, 2021
Phase I portion of the trial will be conducted at the Manchester clinical unit of MAC Clinical Research
Drug Channels
MARCH 12, 2021
Today's guest post comes from Carolyn Zele and Ritupriya Yamujala, Senior Solution Consultants at MMIT. Carolyn and Ritupriya discuss the challenges that manufacturers face in getting payer coverage for new drugs. They argue that a manufacturer can use analogs to improve messaging to payers, identify coverage challenges, and accurately predict payer uptake.
pharmaphorum
MARCH 12, 2021
Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep quality. . The SleepHub device – developed by Barkby group company Cambridge Sleep Sciences – is on the face of it a box and speakers that plays relaxing noises to help you fall asleep more easily, but is underpinned by a sound wave technology that its developer claims prompt the brain into the activity pattern
NY Times
MARCH 11, 2021
Classifying a rare blood disorder as a cancer opened new doors for disease investigation, treatment and hope for a cure.
Pharma Times
MARCH 11, 2021
British drugmaker to expand its clinical manufacturing capacity for cell and gene therapy
Drug Patent Watch
MARCH 11, 2021
Annual Drug Patent Expirations for GENOSYL Genosyl is a drug marketed by Vero Biotech and is included in one NDA. There are six patents protecting this drug. This drug has…. The post New patent for Vero Biotech drug GENOSYL appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 11, 2021
Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease. . The go-to treatment for the five million people worldwide with Parkinson’s is levodopa, which replaces the activity of the dopamine neurotransmitter dopamine that gets depleted by the degeneration of nerve cells in the brain in the disease.
NY Times
MARCH 12, 2021
He was the first hospital official to question the use of an unregulated vitamin injection linked to the deaths of 38 infants. He died of coronavirus complications.
Pharma Times
MARCH 11, 2021
Proceeds will be used to ‘more than triple’ UK biotech's manufacturing capabilities
Drug Patent Watch
MARCH 11, 2021
Annual Drug Patent Expirations for VELPHORO Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Vifor Fresenius drug VELPHORO appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 8, 2021
Austrian health officials have withdrawn a batch of Oxford University/AstraZeneca’s COVID-19 vaccine after two cases of severe coagulation, one of which was fatal. Both patients were treated from the same batch, codenamed ABV 5300, in the district of Zwettl. In a statement the Austrian Federal Office for Safety in Health Care (BASG) said a 49 year-old woman died as a result of severe coagulation disorders, while another women aged 35 developed a pulmonary embolism and is on the way to recovery.
NY Times
MARCH 8, 2021
The industry lacks randomized controlled clinical trials that can clearly establish benefits and risks.
Pharma Times
MARCH 12, 2021
Evidence demonstrates lower incidence rates of COVID-19 in fully vaccinated individuals
Drug Patent Watch
MARCH 11, 2021
Annual Drug Patent Expirations for ANNOVERA Annovera is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent for Therapeuticsmd Inc drug ANNOVERA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 12, 2021
The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung cancers and thyroid cancers, which the company said could herald a new era of genomic medicine for the NHS. The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or che
Pharma Mirror
MARCH 10, 2021
A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five years, mRNA platforms to transform many new non-infectious disease treatment options, and
Pharma Times
MARCH 12, 2021
All waiting time targets for breast cancer were missed in January
Drug Patent Watch
MARCH 11, 2021
Annual Drug Patent Expirations for SUNOSI Sunosi is a drug marketed by Jazz and is included in one NDA. It is available from one supplier. There are six patents protecting…. The post New patent for JAZZ drug SUNOSI appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
145 
Let's personalize your content